Guardant Health, Inc. (NASDAQ:GH) Shares Sold by Bridgewater Associates LP

Bridgewater Associates LP reduced its position in shares of Guardant Health, Inc. (NASDAQ:GH - Free Report) by 30.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 12,544 shares of the company's stock after selling 5,596 shares during the period. Bridgewater Associates LP's holdings in Guardant Health were worth $383,000 at the end of the most recent quarter.

Several other hedge funds have also recently added to or reduced their stakes in GH. Geode Capital Management LLC boosted its holdings in shares of Guardant Health by 1.1% during the 3rd quarter. Geode Capital Management LLC now owns 2,822,220 shares of the company's stock worth $64,754,000 after purchasing an additional 29,686 shares during the last quarter. Exome Asset Management LLC raised its position in shares of Guardant Health by 13.7% during the 3rd quarter. Exome Asset Management LLC now owns 89,800 shares of the company's stock valued at $2,060,000 after buying an additional 10,800 shares during the period. Lord Abbett & CO. LLC acquired a new position in Guardant Health in the third quarter valued at approximately $15,624,000. Fiduciary Alliance LLC grew its position in Guardant Health by 7.6% in the fourth quarter. Fiduciary Alliance LLC now owns 11,879 shares of the company's stock worth $363,000 after acquiring an additional 836 shares during the period. Finally, Wealthcare Advisory Partners LLC acquired a new stake in Guardant Health during the fourth quarter worth $252,000. 92.60% of the stock is owned by institutional investors and hedge funds.

Guardant Health Trading Up 3.8 %

Shares of Guardant Health stock traded up $1.72 on Thursday, hitting $47.36. The stock had a trading volume of 1,407,753 shares, compared to its average volume of 2,139,860. The stock has a market cap of $5.85 billion, a price-to-earnings ratio of -13.30 and a beta of 1.45. Guardant Health, Inc. has a 52-week low of $16.77 and a 52-week high of $50.89. The company's 50 day moving average price is $43.39 and its 200 day moving average price is $36.82.

Guardant Health (NASDAQ:GH - Get Free Report) last issued its quarterly earnings data on Thursday, February 20th. The company reported ($0.90) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by ($0.15). The firm had revenue of $201.81 million during the quarter, compared to analysts' expectations of $192.50 million. Guardant Health had a negative net margin of 59.05% and a negative return on equity of 19,157.20%. Analysts predict that Guardant Health, Inc. will post -2.9 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on GH shares. Stifel Nicolaus increased their price target on Guardant Health from $45.00 to $53.00 and gave the stock a "buy" rating in a report on Friday, February 21st. Morgan Stanley lifted their price target on shares of Guardant Health from $42.00 to $52.00 and gave the company an "overweight" rating in a research report on Thursday, March 6th. Mizuho initiated coverage on shares of Guardant Health in a research report on Thursday, April 10th. They set an "outperform" rating and a $55.00 price objective for the company. Piper Sandler upped their price target on Guardant Health from $34.00 to $50.00 and gave the stock an "overweight" rating in a research note on Wednesday, February 26th. Finally, Scotiabank lifted their price objective on Guardant Health from $47.00 to $52.00 and gave the company a "sector outperform" rating in a research note on Monday, February 24th. Twenty equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $49.00.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.